Immutep Ltd (PRRUF)
OTHER OTC:PRRUF
PRRUF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EST
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.33
Previous CloseN/A
Volume70.00
Average Volume (3M)1.42K
Market Cap
$41.45M
Enterprise Value-$11.64M
Total Cash (Recent Filing)$99.13M
Total Debt (Recent Filing)$2.16M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,473,721,300
10 Day Avg. Volume4,000
30 Day Avg. Volume1,416
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market Cap-0.28
Enterprise Value/Revenue-1.95
Enterprise Value/Gross Profit0.37
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$0.12Price Target Upside200.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$18.63M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA low debt-to-equity ratio and healthy equity base give Immutep structural financial flexibility. For a clinical-stage biotech this reduces default and refinancing risk, supports multi-stage clinical programs, and improves ability to negotiate partnerships or milestone financings over months.
Improving Free Cash Flow TrendAn observed improvement in free cash flow growth suggests the company is making operational progress toward narrowing cash burn. Sustained FCF improvement can extend runway, lower near-term dilution risk and permit more strategic timing for partnerships or non-dilutive funding.
Differentiated LAG‑3 PlatformImmutep’s focused LAG‑3 research and proprietary candidate efti represent a distinct scientific niche. A differentiated immuno-oncology platform increases long-term partnering, licensing, and combination-therapy potential, underpinning durable commercial and strategic options if trials succeed.
Bears Say
Persistent UnprofitabilityNegative margins across gross, EBIT/EBITDA and net indicate the company is not generating operating profits. Persistent unprofitability necessitates external financing to sustain R&D, limits reinvestment flexibility, and raises execution risk until commercial revenues emerge.
Material Negative Cash FlowsMeaningful negative operating and free cash flows imply ongoing cash burn that must be funded externally. Even with improving FCF trends, the structural cash shortfall increases dilution risk and can constrain trial progress or ability to scale operations absent timely partnerships or capital raises.
Revenue Model Reliant On External FundingAs a clinical-stage biotech, Immutep’s revenue depends on collaborations, grants and equity rather than product sales. This structural reliance on non‑recurring funding elevates financing and execution risk and ties progress to partner terms and funding availability until regulatory approvals enable commercial revenues.
Immutep Ltd News
PRRUF FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest stock price was $0.04 and its highest was $0.33 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is $41.45M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 141 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Feb 24, 2026. The company reported -$0.021 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.001.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -$0.021 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in PRRUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.12 (200.00% Upside)
$0.12 (200.00% Upside)
Blogger Sentiment
Bullish
PRRUF Sentiment 96%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
-69.20%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
PRRUF Stock 12 Month Forecast
Average Price Target
$0.12
▲(200.00% Upside)
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―
Ownership Overview
2.21% Insiders
0.08% Mutual Funds
― Other Institutional Investors
97.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---